APLS Q4 2023 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$146M+545.9% YoY

Gross Profit

$126M86.4% margin

Operating Income

-$85M-57.7% margin

Net Income

-$89M-60.5% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+32.6%

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$98M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$789M

Total Liabilities

$594M

Stockholders' Equity

$195M

Cash & Equivalents

$351M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$146M	$23M	+545.9%
Gross Profit	$126M	$20M	+540.7%
Operating Income	-$85M	-$164M	+48.5%
Net Income	-$89M	-$166M	+46.6%

Revenue Segments

Product

$139M95%

Licensing And Other Revenue

$8M5%